Clinical Trials Sponsored by Ivy Life Sciences, Co., Ltd

Total 399 results

Ivy Life Sciences, Co., Ltd

Completed

Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer

Lung Cancer | Liver Cancer | NSCLC Stage IV | Hepatocellular Carcinoma by BCLC Stage | NSCLC Stage IIIB
Nimble Science Ltd.
IGY Life Sciences

Recruiting

Evaluation of the Microbiome in Multiple Sclerosis

Multiple Sclerosis

Canada
Ivy Life Sciences, Co., Ltd
Tri-Service General Hospital

Unknown

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Liver Cancer | HepatoCellular Carcinoma

Taiwan
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine

Pneumococcal Infections

China
Sinovac Life Sciences Co., Ltd.

Active, not recruiting

Immunogenicity，Safety and Cross - Immune Response With Mutant Strains of a Third Dose of an Inactivated COVID-19 Vaccine

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety of an Inactivated SARS-CoV-2 Vaccine for Prevention of COVID-19 in Children and Adolescents

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients

Infection of Upper Respiratory Tract Caused by 2019-nCoV

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Recruiting

SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Recruiting

Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

Tetanus

China
Sinovac Life Sciences Co., Ltd.

Completed

Safety of an Inactivated SARS-CoV-2 Vaccine (CoronaVac) in Children and Adolescents

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Active, not recruiting

Efficacy and Safety of Anti-COVID-19 Antibody SA58 Nasal Spray to Prevent Infection in High-risk Populations

COVID-19

China
Sinovac Life Sciences Co., Ltd.

Completed

Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly

COVID-19

China
Ivy Life Sciences, Co., Ltd
Taipei Veterans General Hospital, Taiwan; Tri-Service General Hospital

Completed

A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy (IVY03)

Non-small Cell Lung Cancer (NSCLC) Stage IV

Taiwan
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Study of RBD1016 in CHB Participants

Chronic Hepatitis b

Sweden
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single and Repeated Dose Escalation of RBD1016 in Subjects With Chronic Hepatitis B Virus (HBV) Infection

Chronic Hepatitis b

China
Suzhou Ribo Life Science Co. Ltd.

Completed

A Single Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of RBD1016

Healthy Volunteers

Australia
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Hyperlipemia

China
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single Ascending Doses Phase I Study to Evaluate the Safety and Pharmacokinetics of RBD4059 in Healthy Subjects

Healthy Volunteers

Australia
Suzhou Ribo Life Science Co. Ltd.

Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Health Volunteer

Australia
YD Global Life Science Co., Ltd.

Unknown

The Study to YD312 Tablet in Patients With Diabetic Macular Edema

Diabetic Macular Edema(DME)

United States, Korea, Republic of
Hangzhou Nuochi Life Science Co., Ltd.

Completed

Measuring the Range of Cardiac Magnetic Parameters in Healthy Subjects by Magnetocardiogram

Healthy People

China
LG Life Sciences
Kyorin Pharmaceutical Co.,Ltd

Completed

Comparison of Efficacy and Safety Between Imidafenacin and Fesoterodine in Patients With Overactive Bladder

Overactive Bladder

Korea, Republic of
Butantan Institute
Sinovac Life Sciences Co., Ltd.

Completed

Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV)

COVID-19

Brazil
Wave Life Sciences Ltd.

Recruiting

Study of WVE-003 in Patients With Huntington's Disease

Huntington Disease

Canada, Spain, Australia, Denmark, Netherlands, Poland, United Kingdom, France, Germany, Italy
Avacta Life Sciences Ltd

Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Soft Tissue Sarcoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Biliary Tract Cancer | Oesophageal Cancer | Cancer of Unknown Primary Site

United States, United Kingdom
Tiziana Life Sciences LTD

Withdrawn

A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease

Crohn's Disease
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease (PRECISION-HD2)

Huntington's Disease

United States, Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Tiziana Life Sciences LTD

Withdrawn

Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS

Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Tiziana Life Sciences LTD

Completed

Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma

Hepatocellular Carcinoma

Israel, Greece, Italy
Wave Life Sciences Ltd.

Terminated

Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)

Duchenne Muscular Dystrophy

United States, Belgium, United Kingdom, Czechia, Canada, France, Italy, Sweden
CANbridge Life Sciences Ltd.

Completed

A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme

Glioblastoma Multiforme

Taiwan
CANbridge Life Sciences Ltd.

Unknown

CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma

Glioblastoma
Clinical Life Sciences Ltd.

Completed

Effect of Plant Stanol Esters on Blood Lipids

Elevated Blood Lipids

Finland
Tiziana Life Sciences LTD

Recruiting

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Secondary Progressive Multiple Sclerosis

United States
Wave Life Sciences Ltd.

Recruiting

A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) (RestorAATion-1)

Alpha-1 Antitrypsin Deficiency

United Kingdom
CANbridge Life Sciences Ltd.

Recruiting

Phase 2 Study of CAN008 in Subjects With GBM

Newly-diagnosed Glioblastoma

China
Wave Life Sciences Ltd.

Terminated

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

ALS | FTD

Netherlands, United Kingdom
Tiziana Life Sciences LTD

Withdrawn

In-patient COVID-19 Study of Intranasal Foralumab

Covid19 | COVID-19 Respiratory Infection | COVID-19 Lower Respiratory Infection
Wave Life Sciences Ltd.

Terminated

Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease (PRECISION-HD1)

Huntington's Disease

Denmark, Canada, Australia, United Kingdom, France, Germany, Poland
Wave Life Sciences Ltd.

Terminated

Open-label Extension Study to Evaluate the Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease

Huntington Disease

Denmark, Australia, Canada, France, United Kingdom, Germany, Poland
Tiziana Life Sciences LTD

Withdrawn

Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM

NAFLD | NASH - Nonalcoholic Steatohepatitis | T2DM (Type 2 Diabetes Mellitus)
Wave Life Sciences Ltd.

Completed

Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Belgium, United Kingdom, France, United States, Italy, Canada, Netherlands
Tiziana Life Sciences LTD

Not yet recruiting

Milciclib in Combination With Gemcitabine in Advanced NSCLC

NSCLC
Wave Life Sciences Ltd.

Active, not recruiting

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Duchenne Muscular Dystrophy

Jordan, United Kingdom
Wave Life Sciences Ltd.

Terminated

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) (FOCUS-C9)

ALS | FTD

Canada, Belgium, New Zealand, Netherlands, Australia, Sweden, United Kingdom, Ireland
Tiziana Life Sciences LTD

Terminated

Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy

Malignant Thymoma

United States, Italy

Clinical Trials Sponsored by Ivy Life Sciences, Co., Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations